{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:11:22Z","timestamp":1792660282816,"version":"4.5.0"},"reference-count":157,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-001"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-009"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"}],"funder":[{"DOI":"10.13039\/100000147","name":"Division of Civil, Mechanical and Manufacturing Innovation","doi-asserted-by":"publisher","award":["CMMI-2027668"],"award-info":[{"award-number":["CMMI-2027668"]}],"id":[{"id":"10.13039\/100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Humanity is experiencing a catastrophic pandemic. SARS-CoV-2 has spread globally to cause significant morbidity and mortality, and there still remain unknowns about the biology and pathology of the virus. Even with testing, tracing, and social distancing, many countries are struggling to contain SARS-CoV-2. COVID-19 will only be suppressible when herd immunity develops, either because of an effective vaccine or if the population has been infected and is resistant to reinfection. There is virtually no chance of a return to pre-COVID-19 societal behavior until there is an effective vaccine. Concerted efforts by physicians, academic laboratories, and companies around the world have improved detection and treatment and made promising early steps, developing many vaccine candidates at a pace that has been unmatched for prior diseases. As of August 11, 2020, 28 of these companies have advanced into clinical trials with Moderna, CanSino, the University of Oxford, BioNTech, Sinovac, Sinopharm, Anhui Zhifei Longcom, Inovio, Novavax, Vaxine, Zydus Cadila, Institute of Medical Biology, and the Gamaleya Research Institute having moved beyond their initial safety and immunogenicity studies. This review analyzes these frontrunners in the vaccine development space and delves into their posted results while highlighting the role of the nanotechnologies applied by all the vaccine developers.<\/jats:p>","DOI":"10.1021\/acsnano.0c07197","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:12:57Z","timestamp":1602234777000},"page":"12522-12537","source":"Crossref","is-referenced-by-count":300,"title":["COVID-19\nVaccine Frontrunners and Their Nanotechnology\nDesign"],"prefix":"10.1021","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-8076","authenticated-orcid":true,"given":"Young\nHun","family":"Chung","sequence":"first","affiliation":[{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Beiss","sequence":"additional","affiliation":[{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven N.","family":"Fiering","sequence":"additional","affiliation":[{"name":"Dartmouth College , , , ,","place":["Hanover, New Hampshire, United States, 03755"]},{"name":"Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center , , ,","place":["Lebanon, New Hampshire, United States, 03766"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-0481","authenticated-orcid":true,"given":"Nicole F.","family":"Steinmetz","sequence":"additional","affiliation":[{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]},{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]},{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]},{"name":"University of California San Diego , , La Jolla , ,","place":["California, United\nStates, 92093"]},{"name":"University of California San Diego , , La Jolla , ,","place":["California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"2026081719085076400_cit1","article-title":"Features, Evaluation and Treatment\nCoronavirus (COVID-19)","volume-title":"StatPearls","author":"Cascella","year":"2020"},{"key":"2026081719085076400_cit2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Ysrafil. Severe\nAcute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An Overview\nof Viral Structure and Host Response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes\nMetab Syndr"},{"key":"2026081719085076400_cit3","unstructured":"WHO Coronavirus Disease (COVID-19)\nDashboard https:\/\/covid19.who.int (accessed 2020-08-3)."},{"key":"2026081719085076400_cit4","unstructured":"Washington, D.\n           of C. 1100 C. A.\nN. S. 1300B; Dc 20036. PolitiFact - Cuomo Accurately Says that Other\nCountries that Reopened Saw an Increase in Coronavirus Infections. https:\/\/www.politifact.com\/factchecks\/2020\/apr\/20\/andrew-cuomo\/cuomo-accurately-says-other-countries-reopened-saw\/ (accessed 2020-08-03)."},{"key":"2026081719085076400_cit5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting\nthe Transmission Dynamics of SARS-CoV-2 through the Postpandemic Period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"key":"2026081719085076400_cit6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome Composition and Divergence\nof the Novel Coronavirus (2019-NCoV) Originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2026081719085076400_cit7","unstructured":"Draft Landscape of COVID-19\nCandidate\nVaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (accessed 2020-08-03)."},{"key":"2026081719085076400_cit8","unstructured":"Moderna\u2019s Work on a COVID-19\nVaccine Candidate, Moderna, Inc. https:\/\/www.modernatx.com\/modernas-work-potential-vaccine-against-covid-19 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit9","unstructured":"Chinese Clinical Trial Register\n(ChiCTR) - The World Health Organization International Clinical Trials\nRegistered Organization Registered Platform. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=52227 (accessed 2020-05-06)."},{"key":"2026081719085076400_cit10","unstructured":"Phase I, Open-Label, Dose-Ranging\nStudy of the Safety and Immunogenicity of 2019-NCoV Vaccine (MRNA-1273)\nin Healthy Adults - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04283461 (accessed 2020-04-01)."},{"key":"2026081719085076400_cit11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0188-3","article-title":"COVID-19 Vaccines:\nBreaking Record\nTimes to First-in-Human Trials","author":"Kim","year":"2020","journal-title":"NPJ. Vaccines"},{"key":"2026081719085076400_cit12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0022-3859.173187","article-title":"The Clinical Development\nProcess for a Novel Preventive Vaccine:\nAn Overview","volume":"62","author":"Singh","year":"2016","journal-title":"J. Postgrad. Med."},{"key":"2026081719085076400_cit13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-Dependent\nEnhancement and SARS-CoV-2 Vaccines and Therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"2026081719085076400_cit14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing MRNA-Vaccine\nTechnologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"2026081719085076400_cit15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/d41586-020-02154-2","article-title":"Coronavirus\nVaccines Get a Biotech Boost","volume":"583","author":"Dance","year":"2020","journal-title":"Nature"},{"key":"2026081719085076400_cit16","article-title":"U.S. Will Pay\n$1.6 Billion to Novavax for Coronavirus Vaccine","author":"Thomas","year":"2020","journal-title":"New York Times"},{"key":"2026081719085076400_cit17","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1056\/NEJMoa2022483","article-title":"An MRNA Vaccine against SARS-CoV-2 \ue5f8 Preliminary Report","volume":"0","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026081719085076400_cit18","unstructured":"Novavax Announces Positive Phase\n1 Data for Its COVID-19 Vaccine Candidate, Novavax Inc. IR Site. https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-announces-positive-phase-1-data-its-covid-19-vaccine (accessed 2020-08-06)."},{"key":"2026081719085076400_cit19","article-title":"Phase 1\/2 Study to\nDescribe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate\n(BNT162b1) in Adults 18 to 55 Years of Age: Interim Report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"2026081719085076400_cit20","article-title":"Concurrent Human Antibody\nand TH1 Type T-Cell Responses Elicited by a COVID-19 RNA Vaccine","author":"Sahin","year":"2020","journal-title":"medRxiv"},{"key":"2026081719085076400_cit21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety,\nTolerability, and Immunogenicity of a Recombinant Adenovirus Type-5\nVectored COVID-19 Vaccine: A Dose-Escalation, Open-Label, Non-Randomised,\nFirst-in-Human Trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2026081719085076400_cit22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety\nof a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy\nAdults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled,\nPhase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2026081719085076400_cit23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity\nof the ChAdOx1 NCoV-19 Vaccine against\nSARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised\nControlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2026081719085076400_cit24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nri2802","article-title":"Immunity and Immunopathology\nto Viruses: What Decides\nthe Outcome?","volume":"10","author":"Rouse","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"2026081719085076400_cit25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and\nY of Immune Responses\nto Viral Vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"2026081719085076400_cit26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody Responses to\nSARS-CoV-2 in Patients of Novel Coronavirus Disease 2019","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2026081719085076400_cit27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T Cell Responses in Patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"2026081719085076400_cit28","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","article-title":"Humoral and Circulating\nFollicular Helper T Cell Responses in Recovered Patients with COVID-19","volume":"26","author":"Juno","year":"2020","journal-title":"Nat. Med."},{"key":"2026081719085076400_cit29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox Vaccine: The Good, the Bad,\nand the Ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"2026081719085076400_cit30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-3292-4_1","article-title":"An Introduction\nto Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global\nEradication","volume":"1387","author":"Minor","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"2026081719085076400_cit31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/v10040167","article-title":"Advances\nin HIV-1 Vaccine Development","volume":"10","author":"Gao","year":"2018","journal-title":"Viruses"},{"key":"2026081719085076400_cit32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/CMR.11.3.430","article-title":"Respiratory Syncytial\nVirus Vaccines","volume":"11","author":"Dudas","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"2026081719085076400_cit33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-Faceted\nFunctions of Secretory IgA at Mucosal Surfaces","author":"Corthesy","year":"2013","journal-title":"Front. Immunol."},{"key":"2026081719085076400_cit34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The Role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain, Behav., Immun."},{"key":"2026081719085076400_cit35","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of Vaccine Administration\nModality on Immunogenicity and Efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert\nRev. Vaccines"},{"key":"2026081719085076400_cit36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing\nMucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J. Immunol."},{"key":"2026081719085076400_cit37","unstructured":"Altimmune COVID-19 Vaccine\nCandidate\nTested at UAB Shows Positive Preclinical Results - News. https:\/\/www.uab.edu\/news\/research\/item\/11426-altimmune-covid-19-vaccine-candidate-tested-at-uab-shows-positive-preclinical-results (accessed 2020-08-14)."},{"key":"2026081719085076400_cit38","unstructured":"OraPro-COVID-19. Home. https:\/\/www.stabilitech.com\/orapro-covid-19\/ (accessed 2020-08-14)."},{"key":"2026081719085076400_cit39","unstructured":"Quadram Researchers Working on\nCOVID-19 Vaccine Join WHO Expert Groups. https:\/\/quadram.ac.uk\/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups\/ (accessed Aug 14, 2020)."},{"key":"2026081719085076400_cit40","doi-asserted-by":"publisher","first-page":"110195","DOI":"10.1016\/j.biopha.2020.110195","article-title":"New Understanding of the Damage of SARS-CoV-2 Infection Outside the\nRespiratory System","volume":"127","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"2026081719085076400_cit41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-Converting\nEnzyme 2 in\nLung Diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"2026081719085076400_cit42","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","article-title":"Angiotensin-converting\nEnzyme 2 in the Brain: Properties\nand Future Directions","volume":"107","author":"Xia","year":"2008","journal-title":"J. Neurochem."},{"key":"2026081719085076400_cit43","article-title":"ACE2 Expression\nby Colonic Epithelial\nCells Is Associated with Viral Infection, Immunity and Energy Metabolism","author":"Wang","year":"2020","journal-title":"medRxiv"},{"key":"2026081719085076400_cit44","article-title":"The Distribution and Functions of Immunoglobulin Isotypes","volume-title":"Immunobiology: The Immune System in Health and Disease,\n5","author":"Charles A Janeway","year":"2001"},{"key":"2026081719085076400_cit45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-Cell-Inducing\nVaccines \u2013 What\u2019s the Future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"key":"2026081719085076400_cit46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/vaccines6040084","article-title":"T Cell\nMemory to Vaccination","volume":"6","author":"Todryk","year":"2018","journal-title":"Vaccines (Basel, Switz.)"},{"key":"2026081719085076400_cit47","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/eji.201141857","article-title":"Immunoglobulin Class Switching Appears\nto Be Regulated by B Cell Antigen Receptor-Specific T Cell Action","volume":"42","author":"Lange","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"2026081719085076400_cit48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jmii.2020.03.015","article-title":"Duration of Serum Neutralizing\nAntibodies for SARS-CoV-2: Lessons from SARS-CoV Infection","volume":"53","author":"Lin","year":"2020","journal-title":"J. Microbiol., Immunol. Infect."},{"key":"2026081719085076400_cit49","unstructured":"Clinical Stage Pipeline\n\u2013\nNovavax \u2013 Creating Tomorrow\u2019s Vaccines Today. Novavax.com. https:\/\/novavax.com\/our-pipeline#nvx-cov2373 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine Adjuvants: Putting Innate\nImmunity to Work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"2026081719085076400_cit51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7007-8-37","article-title":"Immune Mechanisms of\nProtection: Can Adjuvants Rise to the Challenge?","volume":"8","author":"McKee","year":"2010","journal-title":"BMC Biol."},{"key":"2026081719085076400_cit52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040208","article-title":"Antibody-Antigen-Adjuvant\nConjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic\nCells in Cis but Only Have Partial Targeting Specificity","volume":"7","author":"Kreutz","year":"2012","journal-title":"PLoS One"},{"key":"2026081719085076400_cit53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/vaccines8010128","article-title":"Better Adjuvants for Better Vaccines:\nProgress in Adjuvant Delivery\nSystems, Modifications, and Adjuvant\u2013Antigen Codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines (Basel, Switz.)"},{"key":"2026081719085076400_cit54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle Vaccines against Infectious\nDiseases","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"2026081719085076400_cit55","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle\nVaccines Adopting Virus-Like Features for Enhanced Immune Potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"2026081719085076400_cit56","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM\nStructure of the 2019-NCoV Spike in the Prefusion Conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"2026081719085076400_cit57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic Nanoparticle Display of Diverse Influenza\nVirus Hemagglutinins Elicits Broad B Cell Responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"key":"2026081719085076400_cit58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/lrb.2008.1008","article-title":"The Lymphatic System in Health and\nDisease","volume":"6","author":"Cueni","year":"2008","journal-title":"Lymphatic Res. Biol."},{"key":"2026081719085076400_cit59","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.addr.2011.05.017","article-title":"Lymphatic Drug Delivery\nUsing Engineered Liposomes and Solid Lipid Nanoparticles","volume":"63","author":"Cai","year":"2011","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026081719085076400_cit60","unstructured":"eTheRNA Launches an International\nConsortium and Starts Development of Cross-Strain Protective CoV-2\nmRNA Vaccine for High Risk Populations. https:\/\/finance.yahoo.com\/news\/etherna-launches-international-consortium-starts-080000668.html (accessed 2020-09-16)."},{"key":"2026081719085076400_cit61","unstructured":"B.V, I. Intravacc Partners with\nWageningen Bioveterinary Research and Utrecht University to Develop\nan Intranasal COVID-19 Vaccine. https:\/\/www.prnewswire.com\/news-releases\/intravacc-partners-with-wageningen-bioveterinary-research-and-utrecht-university-to-develop-an-intranasal-covid-19-vaccine-301070721.html (accessed 2020-09-16)."},{"key":"2026081719085076400_cit62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 Vaccine Development and\na Potential Nanomaterial Path Forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat.\nNanotechnol."},{"key":"2026081719085076400_cit63","unstructured":"Milken Institute\u2019s COVID-19\nTreatment and Vaccine Tracker Tracks the Development of Treatments\nand Vaccines for COVID-19. https:\/\/covid-19tracker.milkeninstitute.org\/ (accessed 2020-08-03)."},{"key":"2026081719085076400_cit64","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated Virus\nVaccines from Chemistry to Prophylaxis: Merits, Risks and Challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"2026081719085076400_cit65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological Mechanisms of Vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat.\nImmunol."},{"key":"2026081719085076400_cit66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vaccines4020012","article-title":"Recent Advances\nin Subunit Vaccine Carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines (Basel,\nSwitz.)"},{"key":"2026081719085076400_cit67","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1128\/CMR.8.3.406","article-title":"Nucleic Acid Vaccines","volume":"8","author":"Vogel","year":"1995","journal-title":"Clin.\nMicrobiol. Rev."},{"key":"2026081719085076400_cit68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral Vectors for Vaccine Applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin.\nExp. Vaccine Res."},{"key":"2026081719085076400_cit69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as Vaccine Vectors for Infectious\nDiseases\nand Cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"2026081719085076400_cit70","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments\nin Viral Vector-Based\nVaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel, Switz.)"},{"key":"2026081719085076400_cit71","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression\nKinetics of Nucleoside-Modified MRNA Delivered in Lipid Nanoparticles\nto Mice by Various Routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Controlled Release"},{"key":"2026081719085076400_cit72","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4161\/rna.20206","article-title":"RNA Mediated Toll-Like\nReceptor Stimulation in Health and Disease","volume":"9","author":"Dalpke","year":"2012","journal-title":"RNA Biol."},{"key":"2026081719085076400_cit73","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-Specific Recognition of Single-Stranded\nRNA via Toll-Like Receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"2026081719085076400_cit74","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in MRNA Vaccines\nfor Infectious Diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"2026081719085076400_cit75","unstructured":"Safety and\nImmunogenicity Study\nof 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection\n- Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04283461 (accessed 2020-04-03)."},{"key":"2026081719085076400_cit76","unstructured":"Study to Describe the Safety,\nTolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine\nCandidates against COVID-19 in Healthy Adults - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368728 (accessed 2020-05-21)."},{"key":"2026081719085076400_cit77","unstructured":"A Multi-Site, Phase I\/II, 2-Part,\nDose-Escalation Trial Investigating the Safety and Immunogenicity\nof Four Prophylactic SARS-CoV-2 RNA Vaccines against COVID-2019 Using\nDifferent Dosing Regimens in Healthy Adults - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04380701 (accessed 2020-05-21)."},{"key":"2026081719085076400_cit78","unstructured":"A Phase I\/II Study to Determine\nEfficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease\n(COVID-19) Vaccine ChAdOx1 NCoV-19 in UK Healthy Adult Volunteers\n- Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324606 (accessed 2020-05-21)."},{"key":"2026081719085076400_cit79","unstructured":"Phase I Clinical Trial of a COVID-19\nVaccine in 18\u201360 Healthy Adults - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04313127 (accessed 2020-05-27)."},{"key":"2026081719085076400_cit80","unstructured":"A Phase II Clinical Trial to\nEvaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)\n- Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341389 (accessed 2020-05-27)."},{"key":"2026081719085076400_cit81","unstructured":"Safety, Tolerability and Immunogenicity\nof INO-4800 for COVID-19 in Healthy Volunteers - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336410 (accessed 2020-04-10)."},{"key":"2026081719085076400_cit82","unstructured":"INOVIO Announces Positive Interim\nPhase 1 Data For INO-4800 Vaccine for COVID-19. http:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2020\/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19\/default.aspx (accessed 2020-07-21)."},{"key":"2026081719085076400_cit83","unstructured":"A Randomized, Double-Blinded,\nPlacebo-Controlled, Phase I\/II Clinical Trial, to Evaluate the Safety\nand Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell)\nin Healthy Population Aged \u2265 60 Years - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04383574 (accessed 2020-05-21)."},{"key":"2026081719085076400_cit84","unstructured":"Sinovac Reports Positive Data\nfrom Phase I\/II trials of CoronaVac https:\/\/www.clinicaltrialsarena.com\/news\/sinovac-coronavac-data\/ (accessed 2020-08-14)."},{"key":"2026081719085076400_cit85","unstructured":"China\nSinopharm\u2019s Potential COVID-19 Vaccine Triggers Antibodies\nin Clinical Trials: Journal. Reuters. 2020-08-14."},{"key":"2026081719085076400_cit86","unstructured":"Novel Coronavirus (2019-CoV)\nInactivated Vaccine (Vero Cell) Phase I\/II Clinical Trial. http:\/\/www.chictr.org.cn\/showproj.aspx?proj=53003 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit87","unstructured":"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=53003 (accessed\n2020-08-14)."},{"key":"2026081719085076400_cit88","unstructured":"First COVID-19 Inactivated Vaccine\nPerforms Well in Clinical Trials. http:\/\/en.sasac.gov.cn\/2020\/07\/02\/c_5178.htm (accessed 2020-08-14)."},{"key":"2026081719085076400_cit89","unstructured":"An Open Study of the Safety,\nTolerability and Immunogenicity of the Drug \u201cGam-COVID-Vac\u201d\nVaccine against COVID-19 - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04436471 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit90","unstructured":"An Open Study of the Safety,\nTolerability and Immunogenicity of \u201cGam-COVID-Vac Lyo\u201d\nVaccine against COVID-19 - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437875 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/clinomi.07.04.17","article-title":"China\u2019s Zhifei\nStarts Phase II Trial of COVID-19 Vaccine","volume":"7","year":"2020","journal-title":"Reuters"},{"key":"2026081719085076400_cit92","unstructured":"Phase I Clinical\nStudy of Recombinant\nNovel Coronavirus Vaccine - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04445194 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit93","unstructured":"A 2-Part, Phase 1\/2, Randomized,\nObserver-Blinded Study to Evaluate the Safety and Immunogenicity of\na SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2\nRS) with or without MATRIX-MTM Adjuvant in Healthy Subjects\n- Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368988 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit94","article-title":"Vaxine Expects\nto Start Phase II Trials for Potential COVID-19 Vaccine in Weeks","author":"Chowdhury","year":"2020","journal-title":"Reuters"},{"key":"2026081719085076400_cit95","unstructured":"Monovalent Recombinant\nCOVID19\nVaccine - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04453852 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit96","unstructured":"Zydus Cadila\u2019s COVID-19\nVaccine Passes Phase I Safety Trials; Phase II to Test Efficiency\nBegins 6 August - Health News, Firstpost. https:\/\/www.firstpost.com\/health\/zydus-cadilas-covid-19-vaccine-passes-phase-i-safety-trials-phase-ii-to-test-efficiency-begins-6-august-8674891.html (accessed 2020-08-14)."},{"key":"2026081719085076400_cit97","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A\nComprehensive Status Report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"key":"2026081719085076400_cit98","unstructured":"COVID-19 Vaccine\nReaches Phase-2\nTrials in China. http:\/\/english.nmpa.gov.cn\/2020-06\/22\/c_502093.htm (accessed 2020-08-14)."},{"key":"2026081719085076400_cit99","unstructured":"Safety and Immunogenicity Study\nof an Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19\nin People Aged \u2a7e60 Years - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04470609 (accessed 2020-08-14)."},{"key":"2026081719085076400_cit100","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified MRNA Vaccines Protect against\nZika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"Pt A","key":"2026081719085076400_cit101","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.addr.2015.11.005","article-title":"Designing Liposomal\nAdjuvants for\nthe Next Generation of Vaccines","volume":"99","author":"Perrie","year":"2016","journal-title":"Adv. Drug Delivery\nRev."},{"key":"2026081719085076400_cit102","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine\ninto MRNA Yields Superior Nonimmunogenic Vector with Increased Translational\nCapacity and Biological Stability","volume":"16","author":"Kariko\u0301","year":"2008","journal-title":"Mol. Ther."},{"key":"2026081719085076400_cit103","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1021\/ja01096a050","article-title":"Selective\nChemical\nModifications of Uridine and Pseudouridine in Polynucleotides and\nTheir Effect on the Specificities of Ribonuclease and Phosphodiesterases","volume":"87","author":"Naylor","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"2026081719085076400_cit104","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1093\/nar\/23.24.5020","article-title":"Stabilization of RNA Stacking by Pseudouridine","volume":"23","author":"Davis","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"2026081719085076400_cit105","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A Recombinant Receptor-Binding Domain of MERS-CoV in Trimeric Form\nProtects Human Dipeptidyl Peptidase 4 (HDPP4) Transgenic Mice from\nMERS-CoV Infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"key":"2026081719085076400_cit106","unstructured":"A Study\nto Evaluate Efficacy,\nSafety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18\nYears and Older to Prevent COVID-19 - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04470427 (accessed 2020-08-10)."},{"key":"2026081719085076400_cit107","unstructured":"Study to Describe the Safety,\nTolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates\nagainst COVID-19 in Healthy Adults - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368728 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit108","unstructured":"INO-4800 DNA Coronavirus Vaccine https:\/\/www.precisionvaccinations.com\/vaccines\/ino-4800-dna-coronavirus-vaccine (accessed 2020-08-14)."},{"key":"2026081719085076400_cit109","unstructured":"Cohen, J.\n          \n          with Record-Setting\nSpeed, Vaccinemakers Take Their First Shots at the New Coronavirus. https:\/\/www.sciencemag.org\/news\/2020\/03\/record-setting-speed-vaccine-makers-take-their-first-shots-new-coronavirus (accessed 2020-08-14)."},{"key":"2026081719085076400_cit110","unstructured":"Lowe, D.\n          \n          The Russian Vaccine. https:\/\/blogs.sciencemag.org\/pipeline\/archives\/2020\/08\/11\/the-russian-vaccine (accessed 2020-08-14)."},{"key":"2026081719085076400_cit111","unstructured":"Skepticism Greets\nPutin\u2019s Announcement Of Russian Coronavirus Vaccine. https:\/\/www.npr.org\/sections\/coronavirus-live-updates\/2020\/08\/11\/901270401\/skepticism-greets-putins-announcement-of-russian-coronavirus-vaccine (accessed 2020-08-14)."},{"key":"2026081719085076400_cit112","unstructured":"Closing in on\na COVID-19 Vaccine. https:\/\/www.eurekalert.org\/pub_releases\/2020-04\/fu-cio040220.php (accessed 2020-04-19)."},{"key":"2026081719085076400_cit113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385","article-title":"A Novel\nChimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved\nSystems for Vector Derivation and Comparative Immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"2026081719085076400_cit114","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular Mechanisms for Enhanced\nDNA Vaccine Immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"2026081719085076400_cit115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which\nContribute to the Immunogenicity of Non-Replicating Adenoviral Vectored\nVaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"2026081719085076400_cit116","unstructured":"CanSino to Conduct\nPhase III Covid-19 Vaccine Trial in Saudi Arabia. https:\/\/www.clinicaltrialsarena.com\/news\/cansino-vaccine-saudi-trial\/ (accessed 2020-08-10)."},{"key":"2026081719085076400_cit117","unstructured":"A Phase III\nStudy to Investigate a Vaccine against COVID-19. http:\/\/www.isrctn.com\/ISRCTN89951424 (accessed 2020-08-10)."},{"key":"2026081719085076400_cit118","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13312-020-1812-z","article-title":"Coronavirus Vaccine:\nLight at the\nEnd of the Tunnel","volume":"57","author":"Ella","year":"2020","journal-title":"Indian Pediatr."},{"key":"2026081719085076400_cit119","unstructured":"Genexine, Y\nBiologics to Co-Develop Covid-19 Treatment - Korea Biomedical Review. http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=8800 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit120","unstructured":"Japan\u2019s\nAnGes Speeds Toward 2021 Rollout in Coronavirus \u201cVaccine War. https:\/\/www.japantimes.co.jp\/news\/2020\/06\/11\/national\/science-health\/anges-coronavirus-vaccine-war\/ (accessed 2020-08-03)."},{"key":"2026081719085076400_cit121","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/mt.2013.26","article-title":"RNA-Based Vaccination:\nSending a Strong Message","volume":"21","author":"Weiner","year":"2013","journal-title":"Mol. Ther."},{"key":"2026081719085076400_cit122","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-Specific Glycan Analysis of\nthe SARS-CoV-2 Spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"2026081719085076400_cit123","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA Vaccines: Roles against Diseases","volume":"3","author":"Khan","year":"2013","journal-title":"GERMS"},{"key":"2026081719085076400_cit124","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0065-308X(08)60152-9","article-title":"DNA Vaccines: Technology\nand Application as Anti-Parasite and Anti-Microbial Agents","volume":"42","author":"Alarcon","year":"1999","journal-title":"Adv. Parasitol."},{"key":"2026081719085076400_cit125","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral\nDelivery of Self-Amplifying RNA Vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026081719085076400_cit126","article-title":"Lab to Sidestep Drug Industry to Sell Potential Virus Vaccine","author":"Kirkpatrick","year":"2020","journal-title":"New York Times"},{"key":"2026081719085076400_cit127","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective Efficacy\nof in Vitro Synthesized, Specific MRNA Vaccines against\nInfluenza A Virus Infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2026081719085076400_cit128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger\nRNA-Based\nVaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive\nImmune Responses and Provide Antitumor Activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"key":"2026081719085076400_cit129","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of Nonhuman Adenoviruses\nas Vaccine Vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"2026081719085076400_cit130","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1128\/JVI.70.3.1836-1844.1996","article-title":"Analysis of 15 Adenovirus\nHexon Proteins\nReveals the Location and Structure of Seven Hypervariable Regions\nContaining Serotype-Specific Residues","volume":"70","author":"Crawford-Miksza","year":"1996","journal-title":"J. Virol."},{"key":"2026081719085076400_cit131","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1006\/viro.2000.0661","article-title":"Recombinant Bovine\nAdenovirus Type 3 Expressing Bovine Viral Diarrhea Virus Glycoprotein\nE2 Induces an Immune Response in Cotton Rats","volume":"278","author":"Baxi","year":"2000","journal-title":"Virology"},{"key":"2026081719085076400_cit132","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1016\/S0264-410X(02)00344-4","article-title":"Vaccination\nof Puppies Born to Immune Dams with a Canine Adenovirus-Based Vaccine\nProtects against a Canine Distemper Virus Challenge","volume":"20","author":"Fischer","year":"2002","journal-title":"Vaccine"},{"key":"2026081719085076400_cit133","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.vaccine.2004.01.048","article-title":"Recombinant Ovine Atadenovirus Induces a Strong and\nSustained T Cell Response against the Hepatitis C Virus NS3 Antigen\nin Mice","volume":"22","author":"Wu\u0308est","year":"2004","journal-title":"Vaccine"},{"key":"2026081719085076400_cit134","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.virusres.2004.05.003","article-title":"Porcine Adenoviral\nVectors Evade\nPreexisting Humoral Immunity to Adenoviruses and Efficiently Infect\nBoth Human and Murine Cells in Culture","volume":"105","author":"Bangari","year":"2004","journal-title":"Virus\nRes."},{"key":"2026081719085076400_cit135","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1089\/10430349950016636","article-title":"Novel Human Gene Transfer Vectors: Evaluation of Wild-Type\nand Recombinant Animal Adenoviruses in Human-Derived Cells","volume":"10","author":"Rasmussen","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"2026081719085076400_cit136","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.bbrc.2004.12.099","article-title":"Comparative Transduction\nEfficiencies of Human and Nonhuman Adenoviral Vectors in Human, Murine,\nBovine, and Porcine Cells in Culture","volume":"327","author":"Bangari","year":"2005","journal-title":"Biochem.\nBiophys. Res. Commun."},{"key":"2026081719085076400_cit137","doi-asserted-by":"publisher","first-page":"10882","DOI":"10.1128\/JVI.76.21.10882-10893.2002","article-title":"Biology of Ovine Adenovirus Infection of Nonpermissive\nCells","volume":"76","author":"Ku\u0308min","year":"2002","journal-title":"J. Virol."},{"key":"2026081719085076400_cit138","article-title":"Sinovac Says Its Covid-19 Vaccine Generated\nImmune Responses","year":"2020","journal-title":"STAT"},{"key":"2026081719085076400_cit139","unstructured":"China\u2019s\nSinopharm Touts 100% Antibody Response for COVID-19 Vaccine It\u2019s\nAlready Giving to Workers. https:\/\/www.fiercepharma.com\/pharma-asia\/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving (accessed 2020-07-27)."},{"key":"2026081719085076400_cit140","unstructured":"Chinese Researchers\nLaunch Phase-2 Human Test for Possible Coronavirus\nVaccine. Reuters Jun 21, 2020."},{"key":"2026081719085076400_cit141","unstructured":"Zydus to Start\nSecond Phase of Covid-19 Vaccine Candidate Trials Today. https:\/\/www.hindustantimes.com\/india-news\/zydus-to-start-second-phase-of-vaccine-candidate-trials-today\/story-AkiC1iDUI9azdTSVbDFOQM.html (accessed 2020-08-10)."},{"issue":"0","key":"2026081719085076400_cit142","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein\nNanoparticle Vaccine","volume":"0","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026081719085076400_cit143","article-title":"Coronavirus Vaccine\nTracker","author":"Corum","year":"2020","journal-title":"New York Times"},{"key":"2026081719085076400_cit144","unstructured":"Putin Announces\nFirst \u201cRegistered\u201d\nCOVID-19 Vaccine from Russia\u2019s Gamaleya Institute; His Daughter\namong Those Inoculated - Health News, Firstpost. https:\/\/www.firstpost.com\/health\/putin-announces-first-registered-covid-19-vaccine-from-russias-gamaleya-institute-his-daughter-among-those-inoculated-8695031.html (accessed 2020-08-14)."},{"key":"2026081719085076400_cit145","unstructured":"Putin Says Russia has Approved\n\u201cWorld First\u201d Covid-19 Vaccine. But Questions Over Its\nSafety Remain. https:\/\/www.cnn.com\/2020\/08\/11\/europe\/russia-coronavirus-vaccine-putin-intl\/index.html (accessed 2020-08-14)."},{"key":"2026081719085076400_cit146","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a Delta Inulin Microparticle,\nPotentiates In-Built\nAdjuvant Property of Co-Administered Vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"2026081719085076400_cit147","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14712590903431014","article-title":"The Virosomal Adjuvanted Influenza\nVaccine","volume":"10","author":"Calcagnile","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"2026081719085076400_cit148","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development\nand Evaluation of AS03, an Adjuvant System Containing \u03b1-Tocopherol\nand Squalene in an Oil-in-Water Emulsion","volume":"11","author":"Garc\u0327on","year":"2012","journal-title":"Expert\nRev. Vaccines"},{"key":"2026081719085076400_cit149","unstructured":"A Phase 1, Randomized, Double-Blind,\nPlacebo-Controlled, First-in-Human Study to Evaluate the Safety and\nImmunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein\nSubunit Vaccine for COVID-19 in Healthy Volunteers - Full Text View.\nClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405908 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit150","unstructured":"A Randomized, Partially-Blinded,\nDose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and\nImmunogenicity of a Recombinant Coronavirus-Like Particle COVID 19\nVaccine in Adults 18\u201355 Years of Age - Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04450004 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit151","unstructured":"Sanofi: Press Releases, Tuesday,\nApril 14, 2020. https:\/\/www.sanofi.com\/media-room\/press-releases\/2020\/2020-04-14 13\u201300\u201300 2015521 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit152","unstructured":"GSK Allies with Innovax for\nCOVID-19 Vaccine R&D Project. https:\/\/www.fiercebiotech.com\/biotech\/gsk-allies-innovax-for-covid-19-vaccine-r-d-project (accessed 2020-04-09)."},{"key":"2026081719085076400_cit153","unstructured":"GSK Makes Adjuvant Available\nto Coronavirus Vaccine Project. https:\/\/www.fiercebiotech.com\/biotech\/gsk-makes-adjuvant-available-to-coronavirus-vaccine-project (accessed 2020-08-03)."},{"key":"2026081719085076400_cit154","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the\nCpG Adjuvant 1018: A Case Study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol.\nBiol."},{"key":"2026081719085076400_cit155","unstructured":"A Phase I, Prospective, Open-Labeled\nStudy to Evaluate the Safety and Immunogenicity of MVC-COV1901 - Full\nText View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04487210 (accessed 2020-08-03)."},{"key":"2026081719085076400_cit156","unstructured":"Dynavax and Sinovac Announce\nCollaboration to Develop a Coronavirus (COVID-19) Vaccine. Dynavax\nTechnologies Corp.https:\/\/investors.dynavax.com\/news-releases\/news-release-details\/dynavax-and-sinovac-announce-collaboration-develop-coronavirus (accessed 2020-08-03)."},{"key":"2026081719085076400_cit157","unstructured":"Valneva and Dynavax Announce\nCollaboration to Advance Vaccine Development for COVID-19. Valneva. https:\/\/valneva.com\/press-release\/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19\/ (accessed 2020-08-03)."}],"container-title":["ACS Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsnano.0c07197","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/14\/10\/12522\/9527345\/nn0c07197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/14\/10\/12522\/9527345\/nn0c07197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:12:36Z","timestamp":1787040756000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ancac3\/article\/14\/10\/12522\/884188\/COVID-19-Vaccine-Frontrunners-and-Their"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":157,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,9]]},"published-print":{"date-parts":[[2020,10,27]]}},"URL":"https:\/\/doi.org\/10.1021\/acsnano.0c07197","relation":{},"ISSN":["1936-0851","1936-086X"],"issn-type":[{"value":"1936-0851","type":"print"},{"value":"1936-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]}}}